Fassnacht M - Search Results

1

In Situ Metabolomics of Cortisol-Producing Adenomas.

Murakami M, Sun N, Li F, Feuchtinger A, Gomez-Sanchez C, Fassnacht M, Reincke M, Bancos I, Walch A, Kroiss M, Beuschlein F. Murakami M, et al. Among authors: fassnacht m. Clin Chem. 2023 Feb 1;69(2):149-159. doi: 10.1093/clinchem/hvac191. Clin Chem. 2023. PMID: 36544353 Free PMC article.

2

Adrenal incidentalomas: a manifestation of the metabolic syndrome?

Reincke M, Fassnacht M, Väth S, Mora P, Allolio B. Reincke M, et al. Among authors: fassnacht m. Endocr Res. 1996 Nov;22(4):757-61. doi: 10.1080/07435809609043773. Endocr Res. 1996. PMID: 8969938

3

Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line.

Fassnacht M, Beuschlein F, Vay S, Mora P, Allolio B, Reincke M. Fassnacht M, et al. J Endocrinol. 1998 Oct;159(1):35-42. doi: 10.1677/joe.0.1590035. J Endocrinol. 1998. PMID: 9795339

4

Steroidogenic acute regulatory protein mRNA expression in adrenal tumours.

Zenkert S, Schubert B, Fassnacht M, Beuschlein F, Allolio B, Reincke M. Zenkert S, et al. Among authors: fassnacht m. Eur J Endocrinol. 2000 Mar;142(3):294-9. doi: 10.1530/eje.0.1420294. Eur J Endocrinol. 2000. PMID: 10700725

5

Oral glucose tolerance testing but not intravenous glucose administration uncovers hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas.

Beuschlein F, Borgemeister M, Schirra J, Göke B, Fassnacht M, Arlt W, Allolio B, Reincke M. Beuschlein F, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2000 May;52(5):617-23. doi: 10.1046/j.1365-2265.2000.01006.x. Clin Endocrinol (Oxf). 2000. PMID: 10792342

6

ACTH-receptor expression, regulation and role in adrenocortial tumor formation.

Beuschlein F, Fassnacht M, Klink A, Allolio B, Reincke M. Beuschlein F, et al. Among authors: fassnacht m. Eur J Endocrinol. 2001 Mar;144(3):199-206. doi: 10.1530/eje.0.1440199. Eur J Endocrinol. 2001. PMID: 11248736 Review.

7

New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line.

Fassnacht M, Hahner S, Beuschlein F, Klink A, Reincke M, Allolio B. Fassnacht M, et al. Eur J Clin Invest. 2000 Dec;30 Suppl 3:76-82. doi: 10.1046/j.1365-2362.2000.0300s3076.x. Eur J Clin Invest. 2000. PMID: 11281374 Review.

8

Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms.

Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B, Reincke M. Schubert B, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2001 May;54(5):627-32. doi: 10.1046/j.1365-2265.2001.01253.x. Clin Endocrinol (Oxf). 2001. PMID: 11380493

9

Discerning malignancy in adrenocortical tumors: are molecular markers useful?

Wachenfeld C, Beuschlein F, Zwermann O, Mora P, Fassnacht M, Allolio B, Reincke M. Wachenfeld C, et al. Among authors: fassnacht m. Eur J Endocrinol. 2001 Sep;145(3):335-41. doi: 10.1530/eje.0.1450335. Eur J Endocrinol. 2001. PMID: 11517015

10

Expression of HER-2/neu receptor protein in adrenal tumors.

Saeger W, Fassnacht M, Reincke M, Allolio B. Saeger W, et al. Among authors: fassnacht m. Pathol Res Pract. 2002;198(7):445-8. doi: 10.1078/0344-0338-00280. Pathol Res Pract. 2002. PMID: 12234062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

474 results

Search Page

Filters